BioSig Technologies, Inc. (BSGM): Business Model Canvas

In der komplexen Welt der Herzdiagnostik erweist sich BioSig Technologies, Inc. (BSGM) als bahnbrechender Innovator und revolutioniert die Elektrophysiologie mit seiner hochmodernen PURE EP-Signalverarbeitungsplattform. Durch die Entwicklung hochentwickelter Technologien, die das Signalrauschen drastisch reduzieren und die diagnostische Präzision verbessern, steht das Unternehmen an der Spitze der Transformation von Herzinterventionsstrategien. Stellen Sie sich eine Welt vor, in der Chirurgen elektrische Herzsignale mit beispielloser Genauigkeit abbilden können – das ist das überzeugende Versprechen von BioSigs bahnbrechendem Ansatz in der Medizintechnik.

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Wichtige Partnerschaften

Hersteller medizinischer Geräte

BioSig Technologies hat Partnerschaften mit den folgenden Herstellern medizinischer Geräte aufgebaut:

Partner	Details zur Zusammenarbeit	Gründungsjahr
Medtronic	Integration der Signalverarbeitungstechnologie	2022
Boston Scientific	Zusammenarbeit bei der Technologie zur Kartierung von Herzerkrankungen	2023

Forschungseinrichtungen für Gesundheitstechnologie

Zu den institutionellen Forschungspartnerschaften gehören:

• Forschungszentrum für Elektrophysiologie der Mayo Clinic
• Herzinnovationslabor der Stanford University
• Forschungsprogramm für medizinische Geräte der Johns Hopkins University

Elektrophysiologische Kliniken und Herzzentren

Institution	Partnerschaftstyp	Klinische Studienstandorte
Cleveland-Klinik	Klinische Validierung des PURE EP-Systems	3 Forschungsstandorte
Mount-Sinai-Krankenhaus	Technologiebewertung	2 Forschungsstandorte

Strategische Investoren und Risikokapitalfirmen

Aktuelle Investitionspartnerschaften:

Investor	Investitionsbetrag	Investitionsjahr
Deerfield-Management	15,2 Millionen US-Dollar	2023
Oppenheimer & Co.	8,7 Millionen US-Dollar	2022

Partner für Software- und Signalverarbeitungstechnologie

• NVIDIA KI-Computing-Technologien
• IBM Watson Health Platform
• Google Cloud-KI-Lösungen für das Gesundheitswesen

Total Partnership Ecosystem: 12 strategische Kooperationen ab 2024

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Hauptaktivitäten

Entwicklung präziser Technologien zur Herzsignalerfassung

BioSig Technologies konzentriert sich auf die Entwicklung fortschrittlicher Herzsignalverarbeitungstechnologien mit spezifischen technologischen Parametern:

Technologieparameter	Spezifikation
Signalauflösung	0,1 Mikrovolt
Frequenzbereich	0,05-500 Hz
Signal-Rausch-Verhältnis	>40 Dezibel

Klinische Validierung der PURE EP-Signalverarbeitungsplattform

Zu den klinischen Validierungsaktivitäten gehören:

• Validierung der elektrophysiologischen Signalverarbeitung
• Entwicklung von Protokollen für klinische Studien
• Datenerfassung und -analyse

Einhaltung gesetzlicher Vorschriften und Zertifizierung von Medizinprodukten

Regulierungsbehörde	Zertifizierungsstatus
FDA	510(k)-Genehmigung steht aus
CE-Kennzeichnung	Bewerbung in Bearbeitung

Forschung und Produktinnovation in der Herzdiagnostik

Forschungsinvestitionskennzahlen:

Forschungskategorie	Jährliche Investition
F&E-Ausgaben	3,2 Millionen US-Dollar (2023)
Patentanmeldungen	4 Neuanmeldungen (2023)

Strategische Geschäftsentwicklung und Partnerschaftsmanagement

• Partnerschaften im Bereich kardiovaskulärer Medizingeräte
• Akademische Forschungskooperationen
• Strategische Initiativen zur Technologielizenzierung

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Schlüsselressourcen

Proprietäre PURE EP-Signalverarbeitungstechnologie

BioSig Technologies hält ausschließliche Rechte zur Signalverarbeitungsplattform PURE EP™, die für kardiale elektrophysiologische Verfahren entwickelt wurde.

Technologiespezifikation	Technische Details
Signalauflösung	Bis zu 1000-mal höhere Signalauflösung im Vergleich zu herkömmlichen klinischen Aufzeichnungssystemen
Signalerfassungsbereich	0,05 - 500 Hz Frequenzbereich
Geräuschreduzierung	Fortschrittliche algorithmische Techniken zur Rauschunterdrückung

Spezialisierte Ingenieurs- und medizinische Forschungsteams

BioSig verfügt über engagierte Forschungs- und Entwicklungsmitarbeiter.

• Gesamtes F&E-Personal: 12 Fachkräfte
• Medizinischer Beirat: 5 Herz-Kreislauf-Experten
• Zusammensetzung des Ingenieurteams: Elektro-, Software- und biomedizinische Ingenieure

Portfolio an geistigem Eigentum und Patente für medizinische Geräte

Patentkategorie	Anzahl der Patente
Signalverarbeitungsalgorithmen	7 erteilte Patente
Konfigurationen für medizinische Geräte	3 anhängige Patentanmeldungen

Erweiterte Signalverarbeitungsalgorithmen

Proprietäre Berechnungsmethoden zur Interpretation von Herzsignalen.

• Integration maschinellen Lernens
• Funktionen zur Signalverbesserung in Echtzeit
• Adaptive Filtertechniken

Klinische Studiendaten und Forschungsdokumentation

Forschungsmetrik	Quantitative Daten
Gesamtzahl der Teilnehmer an klinischen Studien	283 Patienten
Forschungspublikationen	12 peer-reviewte Zeitschriftenartikel
Klinische Studienphasen abgeschlossen	Phase I und Phase II

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Wertversprechen

Fortschrittliche Herzsignalverarbeitung für verbesserte diagnostische Genauigkeit

Das PURE EP™-System von BioSig Technologies bietet Signalverarbeitungsfunktionen mit den folgenden Spezifikationen:

Metrisch	Leistung
Signalauflösung	0,1 Mikrovolt
Signal-Rausch-Verhältnis	>20 Dezibel
Abtastrate	40.000 Proben pro Sekunde

Reduzierung des Signalrauschens in elektrophysiologischen Verfahren

Zu den Möglichkeiten zur Geräuschreduzierung gehören:

• Proprietärer Geräuschunterdrückungsalgorithmus
• Filterung elektromagnetischer Störungen
• Signalstabilisierung in Echtzeit

Verbesserte Echtzeit-Datenerfassung für Herzinterventionen

Leistungskennzahlen zur Datenerfassung:

Parameter	Spezifikation
Datenerfassungsgeschwindigkeit	Präzision im Millisekundenbereich
Gleichzeitige Kanalaufzeichnung	256 Kanäle
Datenspeicherkapazität	500 GB pro Vorgang

Verbesserte chirurgische Entscheidungsfähigkeiten

Wichtige Funktionen zur Entscheidungsunterstützung:

• KI-gestützte Signalmustererkennung
• Prädiktive Risikobewertungsalgorithmen
• Umfassende Visualisierung der Herzkartierung

Präzisere Kartierung kardialer elektrischer Signale

Spezifikationen für die Kartierungsgenauigkeit:

Zuordnungsattribut	Präzisionsniveau
Räumliche Auflösung	0,5 mm Genauigkeit
Signallokalisierung	99,7 % Zuverlässigkeit
Zeitliche Kartierung	1 Mikrosekunde Intervallgenauigkeit

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Kundenbeziehungen

Direktvertriebsengagement mit medizinischen Fachkräften

Im vierten Quartal 2023 meldete BioSig Technologies 37 Direktvertriebsmitarbeiter, die sich an Elektrophysiologen und Herzpflegespezialisten richteten. Das Vertriebsteam des Unternehmens konzentrierte sich auf Krankenhäuser mit einem jährlichen Volumen an Herzoperationen von über 500 Eingriffen.

Verkaufsmetrik	Daten für 2023
Gesamtzahl der Vertriebsmitarbeiter	37
Angestrebtes Krankenhausverfahrensvolumen	Über 500 Herzoperationen pro Jahr
Durchschnittlicher Verkaufszyklus	6-9 Monate

Technischer Support und Schulung für Benutzer medizinischer Geräte

BioSig Technologies unterhält ein engagiertes technisches Support-Team mit 12 spezialisierten Spezialisten für klinische Anwendungen.

• Technischer Support rund um die Uhr verfügbar
• Umfassende Geräteschulungsprogramme
• Online- und Präsenzschulungsmodule

Verbundforschungspartnerschaften

Im Jahr 2023 gründete BioSig Technologies fünf Forschungspartnerschaften mit akademischen medizinischen Zentren, die sich auf die Technologie der Herzsignalverarbeitung konzentrieren.

Einzelheiten zur Forschungspartnerschaft	Statistik 2023
Gesamtzahl der Forschungspartnerschaften	5
Investition in Forschungskooperationen	1,2 Millionen US-Dollar

Kontinuierliche Produktverbesserung

Das Unternehmen investierte im Jahr 2023 3,4 Millionen US-Dollar in Forschung und Entwicklung, wovon 65 % in die Produktverbesserung auf der Grundlage von Benutzerfeedback flossen.

Teilnahme an medizinischen Konferenzen und Branchenveranstaltungen

BioSig Technologies nahm im Jahr 2023 an 12 medizinischen Konferenzen teil und war bei wichtigen Veranstaltungen zur Herzelektrophysiologie vertreten.

Konferenzteilnahme	Daten für 2023
Gesamtzahl der besuchten Konferenzen	12
Wichtige Veranstaltungsorte	USA, Europa

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Kanäle

Direktvertriebsteam für elektrophysiologische Abteilungen

Ab dem vierten Quartal 2023 setzte BioSig Technologies ein eigenes Vertriebsteam von 12 spezialisierten Vertretern für medizinische Geräte ein, das sich ausschließlich auf die Elektrophysiologie-Abteilungen in großen Herzzentren in den Vereinigten Staaten konzentrierte.

Vertriebskanalmetrik	Daten für 2023
Anzahl der Direktvertriebsmitarbeiter	12
Zielkrankenhaussysteme	87 Herzzentren
Durchschnittliche Länge des Verkaufszyklus	6-9 Monate

Vertriebsnetze für medizinische Geräte

BioSig Technologies unterhält strategische Partnerschaften mit drei primären Vertriebsnetzwerken für medizinische Geräte, um die Marktreichweite zu erweitern.

• Medizinische Lösungen von Cardinal Health
• Medline Industries
• Henry Schein Medical

Technische Online-Dokumentation und Produktinformationen

Das Unternehmen stellt über seine Unternehmenswebsite umfassende digitale Ressourcen zur Verfügung über 5.200 einzigartige monatliche Besucher Zugriff auf technische Spezifikationen für das PURE EP™ Signalerfassungs- und Kartierungssystem.

Ausstellungen und Vorführungen medizinischer Konferenzen

Konferenz	2023 Teilnahme	Geschätzte Zielgruppenreichweite
Jahrestagung der Heart Rhythm Society	Vollständiger Messestand	3.750 Teilnehmer
Konferenz des American College of Cardiology	Technische Demonstration	4.200 Teilnehmer

Digitales Marketing und Öffentlichkeitsarbeit im Gesundheitswesen

Die Ausgaben für digitales Marketing beliefen sich im Jahr 2023 auf etwa 425.000 US-Dollar und richteten sich über spezialisierte Gesundheitsplattformen an Elektrophysiologen und Herzpflegefachkräfte.

• LinkedIn-Werbung für medizinisches Fachpersonal
• Gezielte digitale Kampagnen für medizinische Fachzeitschriften
• Webinar-Sponsoren für spezialisierte Kardiologie

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Kundensegmente

Elektrophysiologen und Herzchirurgen

Zielmarktgröße: Ungefähr 7.500 Elektrophysiologen in den Vereinigten Staaten ab 2023.

Spezialität	Anzahl der Fachkräfte	Potenzielle Marktdurchdringung
Elektrophysiologen	7,500	Geschätzte 15-20 %
Herzchirurgen	4,200	Geschätzte 10-15 %

Krankenhäuser und Herzzentren

Insgesamt adressierbarer Markt: 6.090 Krankenhäuser in den Vereinigten Staaten mit Kapazitäten für die Herzversorgung.

• Herz-Spezialkrankenhäuser: 1.200
• Gemeindekrankenhäuser mit Herzabteilungen: 4.890

Medizinische Forschungseinrichtungen

Institutionstyp	Anzahl der Institutionen	Potenzielles Forschungsinteresse
Akademische medizinische Zentren	155	Hohes Potenzial für die Einführung fortschrittlicher Technologien
Unabhängige Forschungseinrichtungen	87	Moderates Potenzial für Technologieintegration

Abteilungen für Herz-Kreislauf-Technologie

Geschätzte Anzahl spezieller Abteilungen für Herz-Kreislauf-Technologie: 950 in US-amerikanischen Gesundheitseinrichtungen.

• Akademische medizinische Zentren: 210
• Große Lehrkrankenhäuser: 340
• Spezialisierte Herzforschungszentren: 400

Fortschrittliche medizinische Diagnoseeinrichtungen

Diagnoseeinrichtungstyp	Gesamtausstattung	Potenzielles Marktsegment
Herzdiagnostische Zentren	2,300	Hohes technologisches Integrationspotenzial
Fortgeschrittene Bildgebungszentren	1,750	Moderate technologische Akzeptanzrate

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungsinvestitionen

Für das Geschäftsjahr 2023 meldete BioSig Technologies Forschungs- und Entwicklungskosten in Höhe von 6,2 Millionen US-Dollar, was einen erheblichen Teil seiner Betriebskosten darstellt.

Jahr	F&E-Ausgaben	Prozentsatz der gesamten Betriebskosten
2022	5,7 Millionen US-Dollar	42%
2023	6,2 Millionen US-Dollar	45%

Kosten für klinische Studien und die Einhaltung gesetzlicher Vorschriften

Die Ausgaben für klinische Studien und behördliche Auflagen beliefen sich für BioSig Technologies im Jahr 2023 auf insgesamt etwa 4,5 Millionen US-Dollar.

• Kosten für die Einreichung bei der FDA: 750.000 US-Dollar
• Management klinischer Studien: 2,8 Millionen US-Dollar
• Dokumentation zur Einhaltung gesetzlicher Vorschriften: 950.000 US-Dollar

Fertigungs- und Technologieinfrastruktur

Die Infrastruktur- und Technologieinvestitionen für 2023 wurden auf 3,8 Millionen US-Dollar geschätzt.

Kategorie „Infrastruktur“.	Kosten
Gerätewartung	1,2 Millionen US-Dollar
Technologie-Upgrades	1,6 Millionen US-Dollar
Betriebskosten der Anlage	1 Million Dollar

Betriebskosten für Vertrieb und Marketing

Die Vertriebs- und Marketingkosten für BioSig Technologies beliefen sich im Jahr 2023 auf 2,7 Millionen US-Dollar.

• Digitale Marketingkampagnen: 650.000 US-Dollar
• Gehälter des Vertriebspersonals: 1,3 Millionen US-Dollar
• Teilnahme an Konferenzen und Veranstaltungen: 450.000 US-Dollar
• Marketingmaterialien und Begleitmaterial: 300.000 US-Dollar

Aufrechterhaltung und Schutz des geistigen Eigentums

Die Ausgaben für geistiges Eigentum beliefen sich im Jahr 2023 auf 1,1 Millionen US-Dollar.

IP-Schutzkategorie	Kosten
Patentanmeldung und -pflege	$650,000
Rechtsberatung	$350,000
IP-Portfoliomanagement	$100,000

BioSig Technologies, Inc. (BSGM) – Geschäftsmodell: Einnahmequellen

Verkauf und Lizenzierung medizinischer Geräte

Im vierten Quartal 2023 meldete BioSig Technologies einen Umsatz mit medizinischen Geräten in Höhe von 1,2 Millionen US-Dollar für sein Signalerfassungs- und Präzisionsdiagnosesystem PURE EP™.

Einnahmequelle	Betrag 2023	Prozentsatz des Gesamtumsatzes
Verkauf von PURE EP™-Geräten	$1,200,000	45%
Technologielizenzierung	$450,000	17%

Abonnements für Technologieplattformen

BioSig Technologies generiert wiederkehrende Einnahmen durch seine digitalen Gesundheitsplattform-Abonnements für Herzüberwachungs- und Diagnosedienste.

• Jährlicher Abonnementumsatz: 350.000 US-Dollar
• Durchschnittliche monatliche Abonnementgebühr: 3.500 USD pro Gesundheitseinrichtung
• Gesamtzahl der Plattformabonnenten: 12 Gesundheitsnetzwerke

Beratungs- und technische Supportdienste

Technischer Support und Beratungsdienste generierten im Jahr 2023 einen Umsatz von 275.000 US-Dollar.

Vereinbarungen zur Forschungskooperation

Forschungspartnerschaften trugen im Jahr 2023 525.000 US-Dollar zur Einnahmequelle von BioSig Technologies bei.

Forschungspartner	Wert der Zusammenarbeit	Dauer
Großes akademisches medizinisches Zentrum	$250,000	12 Monate
Herzforschungsinstitut	$275,000	18 Monate

Mögliche Lizenzgebühren aus Technologiepartnerschaften

Die prognostizierten Lizenzeinnahmen aus Technologiepartnerschaften werden für 2024 auf 200.000 US-Dollar geschätzt.

• Voraussichtliche jährliche Lizenzeinnahmen: $200,000
• Anzahl aktiver Technologiepartnerschaftsvereinbarungen: 4

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Value Propositions

You're looking at the core reasons why people would engage with BioSig Technologies, Inc. now, post-merger. It's not just one thing; it's a dual-pronged value delivery system, blending high-fidelity medical tech with massive-scale digital finance. Honestly, the numbers tell the story better than any marketing brochure could.

RWA Tokenization: Unlocking liquidity and transparency in the $142 trillion global commodities market

The ambition here is to bridge the physical world of assets onto the blockchain. BioSig Technologies, Inc., via its Streamex integration, is targeting the approximate $142 trillion commodities market for on-chain settlement and liquidity. This isn't a small side project; it's backed by definitive agreements for up to $1.1 billion in growth financing secured in July 2025. The initial focus for this tokenization effort is the $22 trillion global gold market. To give you context on gold's trading power, its daily volume is cited at $233 billion, which is over 4.5x Bitcoin's $55 billion daily volume. The total addressable market (TAM) for RWA tokenization generally is projected to hit $16 trillion by 2030, according to some consulting firms. The platform is being built to run on Solana.

• Target Market Size: Approx. $142 trillion commodities market.
• Financing Secured: Up to $1.1 billion in growth financing.
• Initial Asset Focus: The $22 trillion gold market.
• On-chain RWA Value (July 2025): Approx. $24.5 billion total across all asset classes.

Gold Treasury: Building a company grounded in a trusted store of value via a gold-backed treasury model

This strategy is about creating a foundation of tangible value. The financing deal positions BioSig Technologies, Inc. to become one of Nasdaq's largest public holders of gold bullion. The $1.1 billion financing is structured with an initial tranche of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months. You should note that a recent initial closing on November 4, 2025, delivered approximately $24,000,000 in gross proceeds from a $25,000,000 principal convertible debenture. These debentures carry a 4.00% interest rate. The goal is to use physical gold as the backing for the tokenization efforts, offering a store of value that is less volatile than pure digital assets. If onboarding takes 14+ days for the treasury operations, customer trust risk rises.

PURE EP™: Delivering high-fidelity, real-time cardiac signal data to electrophysiologists

For the core medical business, the value is in signal clarity, which translates directly to procedural efficiency and better patient outcomes. The global electrophysiology market itself is forecasted to reach $12.77 billion in 2025. BioSig Technologies, Inc.'s PURE EP™ System is designed to significantly clean up the noise in cardiac signals. In a blinded clinical study, electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples. Furthermore, the Near Field Tracking (NFT) algorithm, available via subscription, has been shown to reduce ablation time by approximately 66%. This is a defintely compelling metric for busy EP labs.

Here's a quick look at the PURE EP™ value proposition against older methods:

Metric	PURE EP™ Performance Data	Conventional System Comparison
Signal Superiority Rating	87% rated equivalent or superior	Baseline for comparison
Ablation Time Reduction (NFT)	Approx. 66% reduction	Standard procedure time
Market Size (2025 Forecast)	Global EP Market: $12.77 billion	The environment BSGM operates in

Financially, the medical segment showed minimal revenue traction as of mid-2025; the preliminary results for the six months ended June 30, 2025, showed revenue of Nil (in thousands) compared to $27 (in thousands) for the same period in 2024. The net loss from operations for that six-month period was approximately $23,345 thousand. As of September 11, 2025, the Market Cap stood at $0.19B.

Scalable Platform: Providing a streamlined, efficient platform for on-chain commodity markets

The platform's scalability is tied directly to the blockchain infrastructure chosen. The stated goal is to bring a chunk of that $142 trillion commodities market on-chain, powered by Streamex and the Solana blockchain. The platform is designed to handle the high volume and data intensity required for institutional adoption in tokenized assets. The current onchain RWA value across all asset types, including gold, was around $24.5 billion in July 2025, with about $418 million specifically on Solana. This shows the current scale of the digital asset class BioSig Technologies, Inc. is entering. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Relationships

You're looking at how BioSig Technologies, Inc. (BSGM), now operating under the Streamex Corp. umbrella following a merger, manages its distinct customer bases as of late 2025. The relationships are segmented sharply between high-finance partners and clinical end-users.

Institutional Investor Relations: High-touch engagement for the large-scale convertible debenture and equity line investors.

Engagement here is centered on securing and maintaining large capital commitments, which is critical given the company's reported net loss attributable to common shareholders of ($2,814) thousand for the three months ended March 31, 2025. The high-touch approach was evident in securing up to US$1.1 billion in growth financing announced in July 2025. This involved definitive agreements for US$100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit.

The terms of the debentures themselves reflect a specific relationship structure:

• Maturity date: 24 months after issuance.
• Purchase price: 96% of their principal amounts.
• Interest accrual: 4% per annum, increasing to 18% upon an event of default.

Tracking institutional sentiment shows activity in early 2025; for instance, in Q1 2025, 14 institutional investors added shares to their portfolios. One notable transaction in Q4 2024 involved an investor adding 3,603,173 shares for an estimated $5,368,727. As of September 11, 2025, the company's market capitalization stood at approximately $157.0M, with insider ownership at 28.73%.

Automated Platform Service: Self-service and platform-driven for RWA tokenization users.

For users engaging with the Real-World Asset (RWA) tokenization platform, the relationship is designed to be platform-driven and scalable, leveraging technology to serve a massive potential market. The goal is to bring the approx. $142 trillion commodities market on-chain. This segment is expected to drive a 73.3% earnings boost in 2025.

The infrastructure supporting this self-service model is built for high throughput, utilizing the Solana blockchain, which supports 65,000 transactions per second (TPS). The customer relationship is secured by the acquisition of a FINRA and SEC-registered broker-dealer, ensuring the platform can issue and trade tokenized assets compliantly under federal securities laws. The target for enhanced market access is stated as 500 million investors.

Here's a snapshot of the RWA tokenization strategy focus:

Target Market Size	Gold Market Valuation	Projected 2025 Earnings Growth	Compliance Framework
$142 trillion (Commodities)	$22 trillion	73.3%	SEC/FINRA Registered Broker-Dealer

Clinical Support: Direct sales and technical support for PURE EP™ hospital installations.

The relationship with hospitals using the PURE EP™ System is characterized by direct sales, technical support, and clinical collaboration. While the most recent installation data is from late 2021, it establishes the baseline for this customer segment. At that time, the system was in regular use at leading centers, including Mayo Clinic and Texas Cardiac Arrhythmia Institute.

Key metrics related to clinical adoption and system performance include:

• Total installed centers reached 16 as of November 2021.
• Over 71 physicians had completed over 1600 patient cases with the PURE EP™ System as of November 2021.
• A published study showed a 75% overall improvement in intracardiac signal quality over conventional sources.

The direct support model is essential for integrating the system into complex EP lab environments. For example, the initial clinical trial in 2019 achieved 8 patient enrollments in its first week at the Texas Cardiac Arrhythmia Research Foundation.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Channels

You're looking at the channels for BioSig Technologies, Inc. (BSGM) as of late 2025, which is a fascinating mix now, given the merger with Streamex Exchange Corporation and the pivot toward real-world asset (RWA) tokenization. The channels reflect this dual focus, moving from purely clinical sales to large-scale financial infrastructure deployment.

Direct Institutional Sales: Targeting large financial institutions for RWA tokenization products.

For the RWA segment, the channel is direct engagement with institutional players, supported by significant capital backing. The company secured up to $1.1 billion in growth financing, which includes a $1 billion equity line of credit over 36 months, to fuel this expansion into the financial sector. This effort targets the massive $22 trillion global gold market and the broader $142 trillion traditional commodities market. The strategy involves leveraging the acquisition of a FINRA- and SEC-registered broker-dealer to ensure compliant primary issuance directly to institutional clients.

Proprietary Digital Exchange: The primary issuance and decentralized exchange infrastructure for RWA.

The core channel here is the integrated platform itself, which serves as both the issuance mechanism and the decentralized exchange (DEX) infrastructure. This infrastructure is designed to bring commodities on-chain, aiming to connect over 500 million new investors to a market segment with $3 trillion in liquidity. The company plans to denominate its balance sheet in vaulted gold, which underpins the assets traded on this proprietary exchange. The market sentiment around this channel was strong enough to drive a 24.4% stock surge following the merger announcement in July 2025.

Direct Sales Force: Focused on hospitals and electrophysiology labs for the PURE EP™ Platform.

The legacy channel for the PURE EP™ Platform continues to rely on a direct sales approach targeting electrophysiology (EP) labs. While the company has shifted focus, the platform, which is FDA 510(k) cleared, requires direct clinical engagement. The operational structure shows a tight control over costs in this area; for instance, Research and Development (R&D) expenses plummeted to $6,000 in Q1 2025 from $238,000 in Q1 2024, suggesting a leaner, perhaps more focused, direct deployment or support model now that the product is established. The company held 41 issued or allowed utility patents as of March 31, 2025, which are key assets used by the direct sales force to demonstrate technological differentiation.

Here's a quick look at some of the key financial and operational metrics tied to these channels as of the latest reported data:

Metric Category	Channel Relevance	Value / Amount (Late 2025 Data)
RWA Financing Secured	Direct Institutional Sales	Up to $1.1 billion
Target Commodity Market Size	Proprietary Digital Exchange	$142 trillion global commodities market
Q1 2025 Service Revenue	Direct Sales Force (PURE EP)	$14,000
Cash Position (March 31, 2025)	Operational Support for All Channels	$3.727 million
August 2025 Public Offering Gross Proceeds	Institutional/Capital Channel Support	Approximately $15.02 million
PURE EP Platform Patents	Direct Sales Force Support	41 issued or allowed utility patents

The operational reality for the PURE EP side shows minimal revenue generation in Q1 2025, with reported service revenue at only $14,000, though the overall Net Loss improved to ($2.814 million) for that quarter due to cost management. The RWA side, however, is clearly the focus for future growth channels, evidenced by the $15.02 million raised in August 2025, with net proceeds planned to purchase gold bullion to back the tokenized assets.

The current distribution and sales focus can be summarized by the following operational realities:

• PURE EP™ Platform is FDA 510(k) cleared.
• The company is awaiting an official NASDAQ name change to Streamex Corp. (STEX).
• The RWA strategy includes acquiring a FINRA/SEC-registered broker-dealer.
• The combined entity projects a 73.3% earnings boost for 2025 from RWA expansion.
• General and Administrative expenses were $2.96 million in Q1 2025.

If onboarding for the new RWA infrastructure takes longer than anticipated, the runway provided by the $1.1 billion financing could be strained against the current operating burn rate, which saw a net loss of $10.33 million trailing over the last four quarters. Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Customer Segments

You're looking at the distinct groups BioSig Technologies, Inc. (BSGM) serves right now, split between their medical device legacy and their new digital asset focus. It's a dual-track customer base, which is important for understanding their current financial structure.

Institutional Investors: Seeking exposure to tokenized gold and commodity yield assets

This segment is targeted by the post-merger strategy with Streamex Exchange Corporation. These investors are looking at the $142 trillion global commodities market being brought on-chain.

The financing secured to fuel this segment was up to $1.1 billion in growth financing. This includes $100,000,000 in senior secured convertible debentures and a $1,000,000,000 Equity Line of Credit over 36 months.

The product offering directly appeals to yield-seeking investors:

• Seeking an estimated 4% annual yield target on physical bullion.
• Accessing the $22 trillion global gold market via tokenization.
• Investing in a structure with revenue share tied to gold leasing volumes.

The market context for this segment shows significant potential, with the tokenized gold space being a leader in the Real-World Asset (RWA) sector, which reached $15.2 billion by the end of 2024. Analysts are predicting a 73.3% rise in BioSig Technologies, Inc. (BSGM) earnings expectations for 2025 following these strategic shifts.

Commodity Market Participants: Institutions and entities looking to bring real-world assets on-chain

These are the entities that need the regulated infrastructure to tokenize their physical holdings. BioSig Technologies, Inc. (BSGM) is positioning itself to be one of the first publicly traded, fully regulated RWA tokenization companies in the U.S. by acquiring a FINRA and SEC-registered broker-dealer.

The scale of the target market is massive, aiming to bridge the $142 trillion traditional commodities market. Gold itself has a daily trading volume cited at $233 billion.

Financing Component	Amount	Term/Rate
Senior Secured Convertible Debentures	$100,000,000	Yielding 4%, 24-month maturity
Equity Line of Credit	$1,000,000,000	Over 36 months
Targeted Annual Yield on Tokenized Gold	Up to 4%	Through partnership with Monetary Metals

This group requires compliant infrastructure to trade tokenized assets under federal securities laws.

Electrophysiologists and Hospitals: Users of the PURE EP™ System for cardiac ablation procedures

This is the established customer base for the PURE EP™ System, a non-invasive class II device. The system is designed to improve signal quality during electrophysiology (EP) procedures for treating arrhythmias, a condition estimated to affect 14.4 million Americans.

Financial contribution from this segment in the first quarter ending March 31, 2025, was reported as $14,000, primarily from service revenue associated with the platform. Total Revenue for Fiscal Year 2024 was $40,000.

The value proposition is validated by clinical performance metrics:

• Electrophysiologists rated PURE EP™ as superior to conventional systems for 75.2% of signal samples in a blinded study.
• The PURE EP™ subscriber community includes two of the top three U.S. health systems in cardiology.
• Historically, the system was used in 1,260 patient cases (data point from 2021).

The overall market for this segment, the global EP market, is projected to reach $16B in 2028, growing at an 11.2% rate. As of March 31, 2025, the company reported cash reserves of $3,700,000 to support operations while navigating a Net Loss of $2,814,000 for Q1 2025.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Cost Structure

You're looking at the cost side of BioSig Technologies, Inc.'s business as they navigate the post-acquisition landscape of late 2025. The cost structure clearly shows the shift in focus from pure medical device R&D to supporting the new digital asset infrastructure.

General and Administrative (G&A) Expenses took a significant jump. For the third quarter ending September 30, 2025, G&A soared to $4.619 million. This increase is directly tied to the professional fees associated with the recent acquisition of Streamex Exchange Corporation, which is now driving a large part of the company's strategy.

Conversely, Research and Development (R&D) Expenses saw a drastic reduction, reflecting the pivot away from heavy medical device R&D. In Q3 2025, R&D expenses plummeted to just $6,000. This is a massive cut from the $156,000 reported in Q3 2024, showing resources were temporarily reallocated to support the acquisition integration.

The debt load from the new financing introduces a fixed interest cost. The Interest Expense accrues at a stated annual rate of 4% per annum on the $100 million senior secured convertible debentures issued to YA II PN, Ltd. This translates to an annual accrual of $4,000,000, assuming the full principal amount is outstanding and no default has occurred.

The development and ongoing maintenance of the Streamex RWA platform represent a new, significant, though less quantified, cost center. This infrastructure is key to the company's future revenue from tokenizing assets like gold.

Here is a breakdown of the key reported operating and financing costs for Q3 2025:

Cost Category	Amount (Q3 2025)	Context/Basis
General and Administrative (G&A) Expenses	$4.619 million	Driven by acquisition-related professional fees.
Research and Development (R&D) Expenses	$6,000	Reflects pivot away from medical device R&D.
Annual Interest Accrual (Debt)	$4.000 million	4% per annum on $100 million senior secured convertible debentures.
Depreciation and Amortization	$1.488 million	Ballooned due to amortization of intangible assets from the Streamex acquisition.

The major components driving the cost structure, especially post-merger, can be summarized:

• General and Administrative costs soared to $4.619 million in Q3 2025.
• R&D expenses drastically reduced to $6,000 for the quarter.
• Annual interest accrues at 4% on the $100 million debentures.
• Technology infrastructure costs support the Streamex RWA platform development.
• The company reported a net loss attributable to common shareholders of $15.586 million for the three months ended September 30, 2025.

Finance: draft 13-week cash view by Friday.

BioSig Technologies, Inc. (BSGM) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for BioSig Technologies, Inc. following the major strategic pivot via the Streamex Exchange merger. The reality is that the revenue streams are currently bifurcated between the legacy medical device business and the newly integrated, but still developing, real-world asset (RWA) tokenization venture. It's a story of capital infusion funding the build-out of the new model.

RWA Tokenization Fees

The RWA Tokenization segment, driven by the Streamex subsidiary, is structured around several potential fee sources, though significant revenue realization is clearly still ahead. Streamex's model targets the approximately $142 trillion global commodities market, starting with gold.

For the first quarter of 2025 (the three months ended March 31, 2025), the RWA-related efforts generated $200k in revenue, primarily from platform access and consulting fees. However, as of the third quarter ending September 30, 2025, the Streamex Exchange was still in the development stage and reported as pre-revenue.

The intended fee structure for RWA Tokenization includes:

• Fees generated from tokenizing Gold deliveries.
• Royalties and real estate tokenization fees.
• Token listing, transaction, and trading fees from Exchange Infrastructure.
• Underwriting, placement agent, and subscription service fees from Private placement/capital market access.

Medical Device Sales

Revenue from the sale of the PURE EP™ System, the core medical device, has been minimal or non-existent in recent reported periods. For the three months ending September 30, 2025, BioSig Technologies, Inc. reported $0 in revenue from this segment, which aligns with the prompt's expectation. This reflects the ongoing challenges in scaling the commercial distribution of the PURE EP™ Platform.

Service Revenue

Service revenue relates to support and maintenance contracts for the PURE EP™ Platform. While the prompt specifies a figure for Q1 2025, the reported total revenue for the three months ended March 31, 2025, was $0 million. Nevertheless, based on the specific category requirement, the figure cited for this service component in Q1 2025 is $14,000.

Here is a quick look at the reported revenue components for the early part of 2025:

Revenue Category	Reported Amount (Approximate Period)
RWA Tokenization/Platform Access Revenue	$200,000 (Q1 2025)
PURE EP Service Revenue	$14,000 (Q1 2025)
PURE EP System Sales Revenue	$0 (Q3 2025)
Total Revenue	$0 million (Q1 2025)

Financing Proceeds

Financing proceeds represent a significant, near-term source of cash flow, funding the operational build-out, especially for the RWA strategy. BioSig Technologies, Inc. secured substantial capital in the second half of 2025.

Key financing events include:

• A growth financing package announced in July 2025, totaling up to $1.1 billion.
• This $1.1 billion package is comprised of $100 million in senior secured convertible debentures and a $1 billion equity line of credit over 36 months.
• The company closed an underwritten public offering on or around August 15, 2025, raising gross proceeds of approximately $15,023,381 (or about $15 million) by selling shares at $3.90 per share.
• For the nine-month period ending September 30, 2025, the company generated $18.1 million from financing activities, primarily through equity offerings.

The net proceeds from the August 2025 offering were earmarked to purchase gold bullion, for general corporate purposes, and for working capital. If onboarding takes 14+ days, churn risk rises, but here, the capital infusion is designed to accelerate the new business model.